


# Screening for preeclampsia by using maternal serum inhibin A and feto-placental doppler values in the second trimester of pregnancy



Izairi P.<sup>1</sup>, Antovska V. <sup>2</sup>, Skeparovska K.<sup>1</sup>, Velickova N.<sup>3</sup>  
<sup>1,2,3</sup> Special Hospital for Gynecology and Obstetrics “Mother Theresa”, Skopje  
4 Faculty of medical sciences, University “Goce Delcev” Stip  
R. of North Macedonia

## Introduction

Pre-eclampsia is high blood pressure caused by pregnancy. It is one of the most common and life threatening conditions occurring in pregnancy and affects around 1 in 20 pregnant women



## Methodology

**PT** MAYO CLINIC LABORATORIES

Second Trimester Maternal Screening  
Alpha-Fetoprotein (AFP)/Quad Screen  
Patient Information

Patient Information  
Name (last, first, middle) \_\_\_\_\_ Birth Date (mm-yy) \_\_\_\_\_  
Ordering Provider Name (last, first) \_\_\_\_\_ Phone \_\_\_\_\_ Fax \_\_\_\_\_

Reason for Testing  
\_\_\_\_\_  
\_\_\_\_\_

Clinical Information  
1. Serum collection date (mm-yy) \_\_\_\_\_ by ☐ Ultrasound ☐ Last menstrual period  
2. Estimated delivery date (mm-yy) \_\_\_\_\_ by ☐ Ultrasound ☐ Last menstrual period  
Note: Dating method impacts risk calculation and screening performance. Ultrasound dating increases overall screening performance and is required for twin gestations.  
3. Weight \_\_\_\_\_ lbs or \_\_\_\_\_ kg

Clinical History  
4. Insulin-dependent diabetic: ☐ Yes ☐ No Select Yes if patient was on insulin prior to this pregnancy. Otherwise, select No.  
5. Patient race: ☐ Black ☐ Other/Non-black/Mixed  
6. Number of fetuses: ☐ 1 ☐ 2 Risk estimate not available for 3 or more fetuses.  
If twins, number of chorions: ☐ Monochorionic ☐ Dichorionic ☐ Unknown  
7. In-vitro fertilization: ☐ Yes ☐ No The age of the egg affects the risk calculations.  
If egg donor (other than patient), provide donor birth date (mm-yy) \_\_\_\_\_ or current age: \_\_\_\_\_  
If frozen egg or embryo is used, provide egg or embryo freeze date (mm-yy) \_\_\_\_\_  
8. Has the patient had a previous pregnancy with Down syndrome (trisomy 21) or other trisomy? ☐ Yes ☐ No  
9. Has the patient had a previous pregnancy with neural tube defects? ☐ Yes ☐ No  
10. Does the patient or father of the baby have a neural tube defect? ☐ Yes ☐ No  
11. Is this a repeat serum screen? ☐ Yes ☐ No If yes and MayoAccess client, indicate "repeat screen" in performing lab notes.  
12. Current cigarette smoking status: ☐ Smoker ☐ Nonsmoker


General Risk Assessment Information  
\* Neural tube defect risk assessment is available from 15 weeks and 0 days to 22 weeks and 0 days; 15-18 is preferred.  
\* Down syndrome and trisomy 18 risk assessment is available from 14 weeks and 0 days to 22 weeks and 0 days.

Information Required  
\* By providing all information listed above, the most accurate patient-specific risk can be calculated.  
\* An uninterpretable report will be generated when the following are not provided: serum collection date, birth date, estimated date of delivery, and weight.

If you have questions, call 800-533-1710 and ask for the Maternal Screening area.


TS95  
MC1235-1239v0819

\* Inhibin A



## Results

No	Age s	B MI		Blood pressur e (mmHg )	PI/a.uteri na dex.	PI/a.uteri na sin.	PI/a. umbili n A	Inhibi n A
1.	28	25.4	Второ	118/81	0.76	0.81	1.50	258.3
2.	25	23.8	Прво	121/85	0.81	0.79	1.60	850.2
3.	31	26.3	Трето	130/89	0.80	0.79	1.65	560.0
4.	29	26.0	Прво	134/87	1.1	0.90	1.54	1045.7
5.	27	22.5	Прво	129/89	0.90	1.0	1.75	983.1
6.	26	29.0	Прво	115/75	0.75	0.77	1.52	379.4
7.	26	25.3	Второ	118/78	0.78	0.82	1.49	223.4
8.	28	24.9	Прво	130/85	0.98	0.90	1.53	790.2
9.	30	30	Трето	130/87	0.77	0.79	1.64	800.2
10	30	28.3	Трето	125/75	0.83	0.80	1.70	1005.1
11	31	29.1	Прво	124/74	0.95	0.93	1.70	989.9
12	24	19.6	Прво	125/89	0.97	0.82	1.72	1100.0
13	22	21.2	Прво	130/80	0.97	0.71	1.63	887.6
14	21	24.2	Прво	140/79	0.79	0.70	1.68	650.1
15	25	26.4	Второ	121/81	0.90	0.81	1.60	1024.3
16	27	22.2	Прво	115/76	0.81	0.65	1.65	964.5
17	26	20.3	Прво	129/87	0.75	0.76	1.70	705.8
18	30	27.0	Второ	130/85	0.78	0.79	1.68	592.9



## Conclusion

inhibin A levels in maternal serum during second stage pregnancy screening tests can predict incidence and severity of developing preeclampsia in pregnant women

